Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

382 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial.
Shiraishi Y, Nomura S, Sugawara S, Horinouchi H, Yoneshima Y, Hayashi H, Azuma K, Hara S, Niho S, Morita R, Yamaguchi M, Yokoyama T, Yoh K, Kurata T, Okamoto H, Okamoto M, Kijima T, Kasahara K, Fujiwara Y, Murakami S, Kanda S, Akamatsu H, Takemoto S, Kaneda H, Kozuki T, Ando M, Sekino Y, Fukuda H, Ohe Y, Okamoto I. Shiraishi Y, et al. Among authors: sekino y. Lancet Respir Med. 2024 Nov;12(11):877-887. doi: 10.1016/S2213-2600(24)00185-1. Epub 2024 Aug 16. Lancet Respir Med. 2024. PMID: 39159638 Clinical Trial.
A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study).
Shiraishi Y, Hakozaki T, Nomura S, Kataoka T, Tanaka K, Miura S, Sekino Y, Ando M, Horinouchi H, Ohe Y, Okamoto I. Shiraishi Y, et al. Among authors: sekino y. Clin Lung Cancer. 2022 Jun;23(4):e285-e288. doi: 10.1016/j.cllc.2021.10.012. Epub 2021 Oct 25. Clin Lung Cancer. 2022. PMID: 34802879 Clinical Trial.
Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M, Kataoka T, Fujiwara T, Tsukushi S, Takahashi M, Kobayashi E, Yamada Y, Tanaka T, Nezu Y, Hiraga H, Wasa J, Nagano A, Nakano K, Nakayama R, Hamada T, Kawano M, Torigoe T, Sakamoto A, Asanuma K, Morii T, Machida R, Sekino Y, Fukuda H, Oda Y, Ozaki T, Tanaka K. Endo M, et al. Among authors: sekino y. BMC Cancer. 2023 Mar 8;23(1):219. doi: 10.1186/s12885-023-10693-w. BMC Cancer. 2023. PMID: 36890471 Free PMC article.
Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial.
Aokage K, Suzuki K, Saji H, Wakabayashi M, Kataoka T, Sekino Y, Fukuda H, Endo M, Hattori A, Mimae T, Miyoshi T, Isaka M, Yoshioka H, Nakajima R, Nakagawa K, Okami J, Ito H, Kuroda H, Tsuboi M, Okumura N, Takahama M, Ohde Y, Aoki T, Tsutani Y, Okada M, Watanabe SI; Japan Clinical Oncology Group. Aokage K, et al. Among authors: sekino y. Lancet Respir Med. 2023 Jun;11(6):540-549. doi: 10.1016/S2213-2600(23)00041-3. Epub 2023 Mar 6. Lancet Respir Med. 2023. PMID: 36893780 Clinical Trial.
Novel approach of prophylactic radiation to reduce toxicities comparing 2-step40 with 56-Gy simultaneous integrated boost intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the head and neck, an intergroup phase III trial (JCOG1912, NEW BRIDGE).
Yokota T, Zenda S, Kodaira T, Kiyota N, Fujimoto Y, Wasano K, Takahashi R, Mizowaki T, Homma A, Sasaki K, Machida R, Sekino Y, Fukuda H; Japan Clinical Oncology Group Radiation Therapy Study Group; Japan Clinical Oncology Group Head and Neck Cancer Study Group. Yokota T, et al. Among authors: sekino y. BMC Cancer. 2023 Nov 6;23(1):1068. doi: 10.1186/s12885-023-11503-z. BMC Cancer. 2023. PMID: 37932681 Free PMC article. Clinical Trial.
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer with radiologically pure-solid appearance in Japan (JCOG0802/WJOG4607L): a post-hoc supplemental analysis of a multicentre, open-label, phase 3 trial.
Hattori A, Suzuki K, Takamochi K, Wakabayashi M, Sekino Y, Tsutani Y, Nakajima R, Aokage K, Saji H, Tsuboi M, Okada M, Asamura H, Nakamura K, Fukuda H, Watanabe SI; Japan Clinical Oncology Group; West Japan Oncology Group. Hattori A, et al. Among authors: sekino y. Lancet Respir Med. 2024 Feb;12(2):105-116. doi: 10.1016/S2213-2600(23)00382-X. Epub 2024 Jan 3. Lancet Respir Med. 2024. PMID: 38184010 Clinical Trial.
Protocol digest of a phase III randomized trial of gross total resection versus possible resection of fluid-attenuated inversion recovery-hyperintense lesion on MRI for newly diagnosed supratentorial glioblastoma: JCOG2209 (FLAMINGO).
Sekino Y, Sonoda Y, Shibahara I, Mizusawa J, Sasaki K, Sekita T, Ichikawa M, Igaki H, Kinoshita M, Kumabe T, Shibahara J, Ichimura K, Arakawa Y, Fukuda H; Brain Tumor Study Group (BTSG) of the Japan Clinical Oncology Group (JCOG); Narita Y. Sekino Y, et al. Jpn J Clin Oncol. 2024 Sep 17:hyae130. doi: 10.1093/jjco/hyae130. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39292165
[No title available]
[No authors listed] [No authors listed] PMID: 39295330
Risk Factors for Locoregional Relapse After Segmentectomy: Supplementary Analysis of the JCOG0802/WJOG4607L Trial.
Nakagawa K, Watanabe SI, Wakabayashi M, Yotsukura M, Mimae T, Hattori A, Miyoshi T, Isaka M, Endo M, Yoshioka H, Tsutani Y, Isaka T, Maniwa T, Nakajima R, Suzuki K, Aokage K, Saji H, Tsuboi M, Okada M, Asamura H, Sekino Y, Nakamura K, Fukuda H. Nakagawa K, et al. Among authors: sekino y. J Thorac Oncol. 2024 Oct 10:S1556-0864(24)02376-1. doi: 10.1016/j.jtho.2024.10.002. Online ahead of print. J Thorac Oncol. 2024. PMID: 39395662 Free article.
Randomized phase III study comparing re-irradiation stereotactic body radiotherapy and conventional radiotherapy for painful spinal metastases: Japan Clinical Oncology Group study JCOG2211 (RESCORE study).
Kita R, Ito K, Machida R, Sekino Y, Nakamura N, Nakajima Y, Saito T, Imano N, Fukuda H, Ito Y, Mizowaki T; Japan Clinical Oncology Group Radiation Therapy Study Group. Kita R, et al. Among authors: sekino y. Jpn J Clin Oncol. 2024 Oct 21:hyae145. doi: 10.1093/jjco/hyae145. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39431960
382 results